ABT
Abbott Laboratories
NYSE: ABT · HEALTHCARE · MEDICAL DEVICES
$90.79
-0.59% today
Updated 2026-04-29
Market cap
$158.70B
P/E ratio
25.58
P/S ratio
3.52x
EPS (TTM)
$3.57
Dividend yield
2.60%
52W range
$90 – $136
Volume
11.6M
Abbott Laboratories (ABT) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
8 of 8
Last 8 quarters
Avg EPS surprise
+0.7%
Last 4 quarters
Revenue YoY growth
+7.8%
Most recent quarter
EPS YoY growth
+5.5%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-6.6%
Last 3 reports
Positive reaction rate
0%
0 of 3 quarters
Largest single-day move
-11.0%
2026-01-22
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-04-16 | $1.15 | +0.0% | $101.56 | $96.81 | -4.7% |
| 2026-01-22 | $1.50 | +0.7% | $120.73 | $107.42 | -11.0% |
| 2025-10-15 | $1.30 | +0.0% | $133.27 | $127.63 | -4.2% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-03-31 | $1.15 | $1.15 | +0.0% | $11.16B | +7.8% |
| 2025-12-31 | $1.49 | $1.50 | +0.7% | $11.46B | +4.4% |
| 2025-09-30 | $1.30 | $1.30 | +0.0% | $11.37B | +6.9% |
| 2025-06-30 | $0.99 | $1.01 | +2.0% | $11.14B | +7.4% |
| 2025-03-31 | $1.07 | $1.09 | +1.9% | $10.36B | +4.0% |
| 2024-12-31 | $1.34 | $1.34 | +0.0% | $10.97B | +7.2% |
| 2024-09-30 | $1.20 | $1.21 | +0.8% | $10.63B | +4.9% |
| 2024-06-30 | $1.10 | $1.14 | +3.6% | $10.38B | — |
| 2024-03-31 | $0.95 | $0.98 | +3.2% | $9.96B | — |
| 2023-12-31 | $1.19 | $1.19 | +0.0% | $10.24B | — |
| 2023-09-30 | $1.10 | $1.14 | +3.6% | $10.14B | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $5.74 | $48.8B | +10.1% | 17 | high |
| 2027 (E) | $6.32 | $52.6B | +7.8% | 17 | high |
| 2028 (E) | $6.95 | $56.9B | +8.1% | 17 | medium |
| 2029 (E) | $7.62 | $61.4B | +7.9% | 17 | medium |
| 2030 (E) | $8.35 | $66.1B | +7.7% | 17 | medium |
Frequently asked questions
Has Abbott Laboratories beaten earnings estimates?
Abbott Laboratories has beaten Wall Street EPS estimates in 8 of its last 8 quarterly reports, with an average EPS surprise of +0.7% over the last 4 quarters.
How does ABT stock react to earnings?
ABT stock has moved an average of -6.6% in the trading day following earnings over its last 3 reports, with positive reactions in 0% of those quarters.
What is Abbott Laboratories's revenue growth rate?
Abbott Laboratories reported year-over-year revenue growth of +7.8% in its most recent quarter, with EPS growing +5.5% year-over-year.
What is the expected EPS for ABT in 2026?
Analysts expect Abbott Laboratories to report EPS of $5.74 for fiscal year 2026, on revenue of $48.8B, based on estimates from 17 analysts.